Navigation Links
Pfizer Hemophilia presents new data at the World Federation of Hemophilia 2010 Congress
Date:7/8/2010

BUENOS AIRES, ARGENTINA, July 9 Pfizer Inc, the world's leading biopharmaceutical company, today announced that the results of a number of hemophilia studies will be presented at the World Federation of Hemophilia (WFH) 2010 Congress taking place July 10-14, 2010, in Buenos Aires, Argentina. Key research includes a pre-clinical evaluation of recombinant factor Xa as a potential new approach to restoring hemostasis, as well as a study assessing the potential for an engineered recombinant factor VIIa molecule to improve therapeutic outcomes in mouse models of hemophilia. These presentations follow Pfizer's recent announcement about the creation of a new research unit focused on rare diseases, including hemophilia.

"We are very excited to present these data, which highlights the strength of our pipeline and our enduring commitment to provide recombinant products for the hemophilia community," says Brenda Cooperstone, M.D., vice president of clinical development and medical affairs for the Specialty Care Business Unit at Pfizer. "Our investigation of novel therapies for hemophilia treatment remains ongoing and we will continue to work closely with our partnersincluding the World Federation of Hemophiliato help improve hemophilia care worldwide."

Early Research with Factor Xa and VIIa

Pfizer will present the results of a pre-clinical study in mice indicating that recombinant factor Xa therapy may provide a unique way to bypass deficiencies in the intrinsic pathway. Additional results from a preclinical study in mice suggest that a recombinant factor VIIa molecule with increased activity and duration of action may have the potential to improve inhibitor outcomes.

Additional Hemophilia Research from Pfizer at WFH

  • New model of antibody-induced hemophilia A for the assessment of bypass therapies
  • An electronic documentation system in Haemophilia provides otherwise unavailable feedback for continuous qua
    '/>"/>

Contact: Gwen Fisher
Gwen.Fisher@Pfizer.com
484-865-5160
Edelman Public Relations
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Pfizer joins open-access medicinal chemistry public-private collaboration
2. VIDEO from Medialink and National Fibromyalgia Association and Pfizer Inc.: The Science Behind Fibromyalgia
3. Sigma-Aldrich Reaches Agreement to Sell Pfizers Bioactive Small Molecule Compounds
4. Arizona Myeloma Network presents Special Award to TGen president
5. ItsHot.com Presents Aesthetic Diamond Jewelry and Diamond Watches at Wholesale Prices
6. Morehead Presents Webinar on “Managing the Paradox of Employee Alignment and Engagement”
7. RockWest Technology Group Presents Campus Contactless Card Technology at NACCU
8. NextAid Presents BIDS BUILD HOPE Online Auction to Benefit Projects on the Ground in Africa on World AIDS Orphans Day
9. Morehead Presents Webinar on “Creating a High-Performing RN Workforce”
10. AllianceDiamonds.com Presents: Facebook Diamond Giveaway 2010
11. Aderans Research Presents at SID (Society of Investigative Dermatology)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... York (PRWEB) July 25, 2014 As ... forward in U.S. courts, Bernstein Liebhard LLP notes that ... petition by the consumer advocacy group, Public Citizen, to ... In a letter dated May 1, 2014, and released ... the group’s petition for a ban on the marketing ...
(Date:7/25/2014)... A new system that sent patients to designated cardiac ... of sudden cardiac arrest in Arizona, according to a ... Emergency Medicine . , "We knew lives would ... edge guidelines for post-cardiac arrest care and we were ... similar to what is done for Level 1 trauma ...
(Date:7/25/2014)... 25, 2014 CarePoint Health is proud ... Boylan, has joined our network, CarePoint Health Medical Group. ... of highly skilled and experienced physicians comprise CarePoint Health ... practices in Hudson County, representing a wide range of ... provide the highest quality care to patients and families ...
(Date:7/25/2014)... The European liquid chromatography reagents report defines and segments ... of revenue. The liquid chromatography reagents market in Europe ... is estimated to grow to around $1581.8 million by ... to 2018. , Browse through the TOC of the ... of the in-depth analysis provided. This also provides a ...
(Date:7/25/2014)... NH, 7/25/14) Researchers at Dartmouth-Hitchcock Norris Cotton Cancer ... system so it recognizes and attacks invading cancer cells. ... accepting everything as normal, even while cancer cells ... discussed in a review article published this week in ... jumpstart the body,s ability to fight tumors. Nanoparticles ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 4Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 2Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 3Health News:Dr. Boylan Joins CarePoint Health Medical Group 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Scientists test nanoparticle 'alarm clock' to awaken immune systems put to sleep by cancer 2
... , Irvine, Calif., Sept. 26, 2011 Notable levels of ... heart attacks and strokes in people with diabetes and metabolic ... Disease Prevention Program. The researchers also found that individuals ... calcium had cardiac-event risks as low as many without these ...
... R.I. A new study from Rhode Island Hospital researchers ... in patients who are taking non-steroidal anti-inflammatory drugs (NSAIDs) such ... the safety of NSAID medications in clinically relevant animal models ... in the current issue of the journal Surgery . ...
... at Women & Infants Hospital of Rhode Island, Holly ... College of Nurse-Midwives (ACNM), returns to her Rhode Island ... commendation to the Women,s Care Nurse-Midwives. This national ... compassionate midwifery care to families through expanded access, unique ...
... HealthDay Reporter , FRIDAY, Sept. 23 (HealthDay News) -- ... not necessarily living better. And that,s especially true for people who ... expect to live almost six more years of his life with ... the extra time with diabetes is now 2.5 years. "At ...
... 2011) - AMRI (NASDAQ: AMRI) today announced the ... Administration (FDA) regarding its Burlington, Massachusetts aseptic finish-and-fill facility, ... written responses to a August 2010 warning letter and ... actions proposed by AMRI, once fully implemented, should adequately ...
... particular agents during pregnancy could give birth to children with ... The study will be presented today (26 September 2011) ... It is well known that when people are ... However, there has been little research investigating whether a mother,s ...
Cached Medicine News:Health News:Rhode Island Hospital researchers find possible cardiovascular risk with NSAID use 2Health News:Americans Spending More of Their Lives Struggling With Diabetes 2Health News:Americans Spending More of Their Lives Struggling With Diabetes 3Health News:A mother's occupation while pregnant can cause asthma in children 2
(Date:7/24/2014)... , July 24, 2014  PTC Therapeutics, Inc. ... Company will host a webcast conference call to report ... update on the company,s business and outlook on Thursday, ... opening of the market. The call ... (973) 935-8152 (international) five minutes prior to the start ...
(Date:7/24/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the first fiscal quarter ... , Revenues of $47.5 million, up 10% over ... $0.21, up 50% over last year,s comparable quarter. ... $7.2 million, up 20% over last year,s comparable quarter. ...
(Date:7/24/2014)... IGI Laboratories, Inc. (NYSE MKT: IG), a ... pharmaceutical company, today announced it has accepted  Damian ... Finio has accepted a senior level finance position at ... acceptance of his new position, Mr. Finio will be ... IGI Laboratories, Inc.  The effective date of his resignation ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... Nov. 2, 2011 LORENZ customers and business partners have ... Article 57(2) of Regulation (EC) 726/2004 and its impact on ... Interest Group for EVMPD – XEVPRM. One of ... registration are the Requirements of Article 57(2) of Regulation (EC) ...
... GenVec, Inc. (Nasdaq: GNVC ) will report financial ... 9, 2011, before the U.S. financial markets open. The announcement ... 10:00 a.m. EST to discuss the company,s third quarter financial ... the live conference call, please dial 877-558-0567 (U.S. or Canada) ...
Cached Medicine Technology:LORENZ' Response to New EU PV Legislation - Regulation No. 1235/2010 and EVMPD 2GenVec to Release Third Quarter 2011 Financial Results and Conduct a Conference Call on November 9, 2011 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: